Publicação

The Bayer-Monsanto deal: one of the worst corporate deals ever

Ver documento

Detalhes bibliográficos
Resumo:This case describes the long-lasting acquisition process of Monsanto by the Germany-based multinational company Bayer, that was closed in June 2018. Given the rising skepticism and resistance regarding the deal on the part of both Bayer’s stakeholders and shareholders, the case will particularly focus on the rationale of the transaction and the motivation of the management board to keep their commitment to the acquisition while reflecting on the Corporate Governance of Bayer as well. Apart from the strategic reasons, the case also addresses the issues that arose in the course of the process and discusses whether the exceptionally high acquisition premium is justified or not.
Autores principais:Ongun, Aylin
Assunto:Mergers and acquisitions Corporate finance Synergies Corporate governance Stakeholder activism
Ano:2020
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade Nova de Lisboa
Idioma:inglês
Origem:Repositório Institucional da UNL
Descrição
Resumo:This case describes the long-lasting acquisition process of Monsanto by the Germany-based multinational company Bayer, that was closed in June 2018. Given the rising skepticism and resistance regarding the deal on the part of both Bayer’s stakeholders and shareholders, the case will particularly focus on the rationale of the transaction and the motivation of the management board to keep their commitment to the acquisition while reflecting on the Corporate Governance of Bayer as well. Apart from the strategic reasons, the case also addresses the issues that arose in the course of the process and discusses whether the exceptionally high acquisition premium is justified or not.